#USA #cancer detection #Foster City #ADELA #MRD Testing

Adela Advances Multi-Cancer Early Detection Study at 2026 ASCO Meeting

Adela, Inc., a pioneer in the field of blood testing, is making tremendous strides in improving cancer detection methodologies. At the recent 2026 ASCO Annual Meeting, the company presented key updates regarding its groundbreaking study focused on Multi-Cancer Early Detection (MCED). This innovative study utilizes a proprietary genome-wide methylome enrichment technology designed to enhance molecular residual disease (MRD) monitoring and promote early identification of cancer.

Key Highlights from the CAMPERR Study

The CAMPERR study, registered under NCT05366881, has successfully enrolled 6,300 participants at various sites nationwide across the United States. As of now, an impressive 98% of participants have been accounted for, and the enrollment phase is anticipated to conclude by the end of 2026. This extensive study is designed to train and validate a blood test that can detect multiple types of cancer early on, which has been a long-standing challenge in oncology.

Dr. Anne-Renee Hartman, the Co-Founder and Chief Medical Officer of Adela, emphasized, "CAMPERR is one of the most comprehensive prospective observational MCED studies conducted to date. The diversity and scale of this study provide significant confidence that our lab-developed test will be effective across various demographics."

The study focuses primarily on two categories of participants: approximately 2,400 individuals who have recently been diagnosed with cancer or are undergoing treatment for cancer recurrence, and 3,900 cancer-free control participants. The targeted cancer types represent an astonishing 93% of annual cancer incidence and 88% of annual cancer mortality in the U.S. Furthermore, participants diagnosed with Stage I–III lung cancer will be re-evaluated with additional blood samples to assess the sensitivity of the test for MRD-based recurrence detection.

Innovative Technology Behind the Testing

Adela’s technology stands out in the realm of methylation-based MCED testing. Instead of relying on conventional methodologies that utilize enzymatic or chemical treatments, Adela employs a unique high-affinity enrichment process. This approach not only preserves more genomic material for deeper sequencing but also aids in capturing a broader range of cancer signals from the blood, especially for early-stage cancers where the detectable DNA is at minimal levels.

Dr. Daniel De Carvalho, Co-Founder and Chief Scientific Officer, highlighted the significance of their methylome technology by stating, "The methylome holds vital cancer signals, crucial for early detection and localizing the cancer origin. Our advanced enrichment platform facilitates this process without compromising the integrity of the cfDNA."

Future Prospects and Presentations

In addition to presenting findings from the CAMPERR study, Adela also shared exciting data on the use of an updated classifier to detect recurrence in head and neck squamous cell carcinoma (HNSCC). Adela's current MRD tests are already being utilized by select providers to monitor recurrence in head and neck cancers, with plans for expansion into solid tumor monitoring for those receiving immunotherapy by the end of this year.

Noteworthy presentations from Adela included:

• - Abstract 6084: Evaluation of a tissue-free genome-wide methylome enrichment assay for detecting MRD in HNSCC patients, led by Dr. Geoffrey Liu on May 30, 2026.
• - Abstract TPS10628: A detailed look into the multicenter, prospective, observational study to analyze cfDNA-based assays for MCED, presented by Dr. Gregory Idos on June 1, 2026.

Adela’s advancements present a promising leap toward elevating cancer detection methods, potentially transforming how clinicians monitor and treat cancer patients. For more information on their research and ongoing studies, visit adelabio.com.